

**Regd. Office :**  
'Zydus Tower',  
Satellite Cross Roads,  
Ahmedabad 380 015. India.  
Phone : +91-79-2686 8100 (20 Lines)  
Fax : +91-79-2686 2368  
www.zyduscadila.com  
CIN:L24230GJ1995PLC025878

<b>BSE Limited</b> 1 <sup>st</sup> Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
<b>Kind Attn.:</b> Mr. Sanjay Golecha / Mr. Gopalkrishnan	<b>Kind Attn.:</b> Famroze Pochara Asst. Vice President
<b>Date:</b> September 16, 2017	
<b>Re.:</b> Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated September 16, 2017 titled "Zydus' Neshar Pharmaceuticals gets USFDA final approval for Oseltamivir Powder for Oral Suspension".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

  
**UPEN H. SHAH**  
**COMPANY SECRETARY**



Encl.: As above

## **Zydus' Neshor Pharmaceuticals gets USFDA final approval for Oseltamivir Powder for Oral Suspension**

*Ahmedabad, 16 September 2017*

Zydus' Neshor Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA received final approval from the USFDA to market Oseltamivir Powder for Oral Suspension, 6 mg/ml which is used in the treatment and prevention of influenza.

It will be produced at the Neshor Pharmaceuticals' manufacturing facility located at St. Louis, MO, USA. The sales of Oseltamivir Powder for Oral Suspension are estimated at \$367.92 million. *Source: IMS Health, IMS National Sales Perspective Audit, MAT July 2017, extracted September 2017.*

The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.